Effective treatment of low risk acute GVHD with itacitinib monotherapy
Last Updated: Tuesday, October 4, 2022
A phase 2 trial evaluated itacitinib, a selective JAK1 inhibitor, in 70 patients with low risk acute GvHD, versus 140 who were treated with standard-of-care high dose systemic corticosteroids. It found that itacitinib resulted in fewer serious infections compared to systemic corticosteroids.
Advertisement
News & Literature Highlights